Median age was 60.5 years (range, 34-75); 83.7% of patients had

### RESULTS

#### Best response, n (%)

- CR, complete response; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease.

#### Median DOR, months (95% CI)

- The overall response rate was 83.7% (95% CI: 76.0-89.6%) with 77.9% complete response (CR) (Table 2).
- Most patients achieved a response by the first efficacy assessment; median time to response was 2.73 months.
- Median duration of response was not reached; the estimated 30-month event-free (progressive disease/death) rate was 47.6% (95% CI: 36.2-58.1%) (Figure 3).

#### Median duration of response was not reached; the estimated 30-month event-free (progressive disease/death) rate was 47.6% (95% CI: 36.2-58.1%) (Figure 3).

#### Safety

- The most common grade ≥3 AEs were hypertension (33%), neutropenia (26%), and anemia (16%).
- The most common grade ≥3 laboratory toxicity was neutrophil count decreased (48.8%)
- The safety profile was largely unchanged with longer follow-up (18.4 months follow-up).

#### DISCUSSION

- Response was generally consistent across all subgroups (Table 3).
- ORR was similar in patients with or without bulky disease and lymphatic involvement.
- The safety profile was largely unchanged with longer follow-up (18.4 months follow-up).

### CONCLUSIONS

- Zanubrutinib is an effective and well-tolerated therapy for R/R MCL.
- Response and safety were consistent with longer follow-up.
- The safety profile was largely unchanged with longer follow-up (18.4 months follow-up).

### DISCLOSURES

- The results of this study have been published in blood urine present, 2019;134:851-859.
- The results of this study have been published in blood urine present, 2019;134:851-859.
- The results of this study have been published in blood urine present, 2019;134:851-859.
- The results of this study have been published in blood urine present, 2019;134:851-859.